BR0110947A - Novo processo - Google Patents

Novo processo

Info

Publication number
BR0110947A
BR0110947A BR0110947-2A BR0110947A BR0110947A BR 0110947 A BR0110947 A BR 0110947A BR 0110947 A BR0110947 A BR 0110947A BR 0110947 A BR0110947 A BR 0110947A
Authority
BR
Brazil
Prior art keywords
new process
stable
formoterol
copd
rhinitis
Prior art date
Application number
BR0110947-2A
Other languages
English (en)
Other versions
BRPI0110947B8 (pt
BRPI0110947B1 (pt
Inventor
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0110947(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0110947A publication Critical patent/BR0110947A/pt
Publication of BRPI0110947B1 publication Critical patent/BRPI0110947B1/pt
Publication of BRPI0110947B8 publication Critical patent/BRPI0110947B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Separation By Low-Temperature Treatments (AREA)

Abstract

"NOVO PROCESSO". A invenção refere-se a uma composição farmacêutica estável útil no tratamento de distúrbios respiratórios tais como asma, rinite e doença pulmonar obstrutiva crónica (COPD) e um novo processo de micronização para a preparação de uma formulação estável de formoterol ou seus enantiómeros e um veículo/diluente compreendendo um carboidrato tal como lactose.
BRPI0110947A 2000-05-19 2001-05-17 processo para a preparação de uma composição farmacêutica e composição farmacêutica assim obtida BRPI0110947B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012261.4A GB0012261D0 (en) 2000-05-19 2000-05-19 Novel process
PCT/SE2001/001117 WO2001089491A1 (en) 2000-05-19 2001-05-17 Novel process

Publications (3)

Publication Number Publication Date
BR0110947A true BR0110947A (pt) 2003-04-29
BRPI0110947B1 BRPI0110947B1 (pt) 2016-12-27
BRPI0110947B8 BRPI0110947B8 (pt) 2021-05-25

Family

ID=9892016

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0110947A BRPI0110947B8 (pt) 2000-05-19 2001-05-17 processo para a preparação de uma composição farmacêutica e composição farmacêutica assim obtida

Country Status (19)

Country Link
US (3) US7179489B2 (pt)
EP (1) EP1289505B1 (pt)
JP (3) JP5739597B2 (pt)
KR (1) KR100799452B1 (pt)
CN (1) CN1245962C (pt)
AT (1) ATE276748T1 (pt)
AU (2) AU5900601A (pt)
BR (1) BRPI0110947B8 (pt)
CA (1) CA2409660C (pt)
DE (1) DE60105807T2 (pt)
ES (1) ES2227190T3 (pt)
GB (1) GB0012261D0 (pt)
IL (2) IL152532A0 (pt)
MX (1) MXPA02011310A (pt)
NO (1) NO20025220D0 (pt)
NZ (1) NZ522419A (pt)
PT (1) PT1289505E (pt)
WO (1) WO2001089491A1 (pt)
ZA (1) ZA200208710B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
NZ538965A (en) 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
US20040105821A1 (en) * 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
ES2284025T3 (es) * 2003-07-29 2007-11-01 Boehringer Ingelheim International Gmbh Medicamentos para inhalar que comprenden betamimeticos y un anticolinergico.
PT1670482E (pt) 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2005123072A1 (en) * 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
MX2007009656A (es) 2005-02-10 2007-11-07 Glaxo Group Ltd Proceso para elaborar lactosa utilizando tecnicas de clasificacion previa y formulaciones farmaceuticas formadas de la misma.
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010144043A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab A novel 4-methylbenzenesulphonate salt and a process for preparing a pharmaceutical composition comprising the salt
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
EP2538922B1 (en) * 2010-02-25 2016-04-06 Andi-Ventis Limited Formulation of compositions for the treatment of inflammatory conditions
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
EP2804583A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
NZ629438A (en) * 2012-02-28 2016-10-28 Iceutica Holdings Inc Inhalable pharmaceutical compositions
CA3150240A1 (en) 2019-09-24 2021-04-01 Tomaso GUIDI Dry powder formulation for a dry powder inhaler, with a combination of spheronised particles and coarse particles, and a dry powder inhaler comprising the formulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
EP0525388B1 (de) * 1991-07-01 1995-09-20 Gerhard Dr. Gergely Lutsch- oder Kautablette
JPH0558911A (ja) * 1991-08-27 1993-03-09 N D Shinyaku Kaihatsu Kenkyusho:Kk 鎮咳去痰剤
DK0613371T3 (da) 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700136D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
US6034604A (en) * 1999-01-14 2000-03-07 Kaltner; George Deactivation prevention for electronic article surveillance systems
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
US20030129245A1 (en) 2003-07-10
JP5739597B2 (ja) 2015-06-24
US7179489B2 (en) 2007-02-20
DE60105807T2 (de) 2005-11-24
KR20030001514A (ko) 2003-01-06
PT1289505E (pt) 2005-01-31
US20070259048A1 (en) 2007-11-08
WO2001089491A1 (en) 2001-11-29
AU5900601A (en) 2001-12-03
NZ522419A (en) 2003-08-29
IL219785A (en) 2015-10-29
MXPA02011310A (es) 2003-04-25
ZA200208710B (en) 2004-02-10
IL152532A0 (en) 2003-06-24
CA2409660A1 (en) 2001-11-29
AU2001259006B2 (en) 2005-03-24
BRPI0110947B8 (pt) 2021-05-25
ES2227190T3 (es) 2005-04-01
CN1245962C (zh) 2006-03-22
CN1429103A (zh) 2003-07-09
DE60105807D1 (de) 2004-10-28
KR100799452B1 (ko) 2008-01-30
EP1289505A1 (en) 2003-03-12
JP2015042693A (ja) 2015-03-05
JP2013040214A (ja) 2013-02-28
US20100183729A1 (en) 2010-07-22
NO20025220L (no) 2002-10-31
ATE276748T1 (de) 2004-10-15
US7670625B2 (en) 2010-03-02
NO20025220D0 (no) 2002-10-31
EP1289505B1 (en) 2004-09-22
GB0012261D0 (en) 2000-07-12
JP2003534272A (ja) 2003-11-18
CA2409660C (en) 2011-02-08
BRPI0110947B1 (pt) 2016-12-27
IL219785A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
BR0110947A (pt) Novo processo
IL152470A0 (en) Pharmaceutical composition comprising micronised formoterol and micronised glucocorticosteroid
IS6444A (is) Pýrimidín karboxamíð nytsamleg sem latar á PDE4 samsætuensím
SE0200356D0 (sv) Novel use
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
DE60120936D1 (de) Behandlung von atemerkrankungen
SE9900833D0 (sv) Novel combination
DE50307184D1 (de) Kombination von loteprednoletabonat und dfho zur behandlung von atemwegserkrankungen, allergischen erkrankungen, asthma und copd
SE9900834D0 (sv) Novel combination
DK1490103T3 (da) Fremgangsmåde til fremstilling af en farmaceutisk sammensætning omfattende Mycobacterium w til behandling af astma (obstruktiv lungesygdom)
BR0303387A (pt) Método para o tratamento de asma, mycobacterium w, e, processo para a fabricação de uma composição farmacêutica utilizável para o tratamento de asma

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 17/05/2021